Molecular Diagnostics Point of Care Market - SINGLE USER

Molecular Diagnostics Point of Care Market - SINGLE USER

Global Molecular Diagnostics Point of Care Market: Focus on Application, Technology, Type, End User, Country Data (15 Countries), and Competitive Landscape – Analysis and Forecast, 2019-2029

€4,600.00

Details

Key Questions Answered in this Report:

• What are the major market drivers, challenges, and opportunities in the global molecular diagnostic point of care market?
• What are the factors resulting in the emerging trends within the global molecular diagnostic point of care market?
• How is each segment of the global molecular diagnostic point of care market expected to grow during the forecast period and what is the estimated revenue to be generated by each of the segments by the end of 2029?
• What is the expected compound growth rate to be witnessed by the leading players in the market during the forecast period 2019-2029?
• What are the key applications in the global molecular diagnostic point of care market? What are the major segments of these applications?
• Who are the key manufacturers the global molecular diagnostic point of care products, and what are their contributions?
Global Molecular Diagnostic Point of Care Market Forecast, 2019-2029
The global molecular diagnostic point of care industry analysis by BIS Research projects the market to grow at a significant CAGR of 12.14% during the forecast period, 2019-2029. The molecular diagnostic point of care market generated $1,689.6 million revenue in 2018, in terms of value.
The molecular diagnostic point of care market growth has been primarily attributed to the major drivers in this market such as highly increasing global prevalence of infectious diseases and various types of cancer, growing demand for non-invasive diagnostics, increase in adoption of personalized medicines on a global level, and significant external funding for executing research and development exercises. The challenges include an uncertain reimbursement scenario, a lack of high-complexity testing centers, and high capital requirement hampering the global reach.
Expert Quote
“There is no doubt that near-patient molecular testing represents the future of diagnosing infectious diseases, especially those like influenza that are highly transmissible.”
Scope of the Market Intelligence on Global Molecular Diagnostic Point of Care Market
The molecular diagnostic point of care research provides a holistic view of the market in terms of various factors influencing it, including regulatory reforms, and technological advancements.
The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the diagnostic market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global molecular diagnostic point of care market.
Market Segmentation
The molecular diagnostic point of care market is segmented into infectious disease, oncology, prenatal testing and other applications, on the basis of application.
The molecular diagnostic point of care market is segmented into polymerase chain reaction, isothermal nucleic acid amplification technology and other methods, on the basis of technology.
The molecular diagnostic point of care market is segmented into assays, systems and software, on the basis of type.
The molecular diagnostic point of care market is segmented into hospitals, clinics, diagnostic centers, and other end-users, on the basis of end-user.
The molecular diagnostic point of care market is segmented into North America, Europe, Asia-Pacific, Latin America and Rest-of-the-World, on the basis of geography.
Key Companies in the Molecular Diagnostic Point of Care Market
The key manufacturers who have been contributing significantly to the molecular diagnostic point of care market include Hologic, Inc., Abbott Laboratories, bioMerieux S.A., QIAGEN N.V., Quidel Corporation, Biocartis NV, Danaher Corporation, DiaSorin S.p.A., F. Hoffman-La Roche Ltd., Luminex Corporation, Mesa Biotech, QuantuMDx Group Ltd., Spartan Biosciences Inc., DxNA LLC, and Abacus Diagnostica Oy, among others.
Executive Summary
1 Research Scope and Methodology
1.1 Scope of the Study
1.2 Research Methodology
1.3 Data Sources
1.4 Assumptions and Limitations
1.5 Data and Prediction Modeling

2 Market Overview
2.1 Market Available Molecular Diagnostics Point of Care Products
2.2 Molecular Diagnostics Point of Care in Clinical Diagnostics
2.3 Molecular Diagnostics Point of Care Technologies
2.4 Regulatory Framework
2.4.1 Legal Requirements and Framework in U.S.
2.4.2 Legal Requirements and Framework in Europe
2.4.3 Legal Requirements and Framework in Asia-Pacific
2.4.3.1 China
2.4.3.2 Japan
3 Market Dynamics
3.1 Overview
3.2 Impact Analysis
3.3 Market Drivers
3.3.1 Growing Demand for Non-Invasive Diagnosis
3.3.2 Increasing Prevalence of Infectious Diseases and Various Types of Cancer on a Global Level
3.3.3 Increase in Adoption of Personalized Medicine Shifting the Paradigm from Reaction to Prevention on a Global Level
3.3.4 Significant External Funding for Executing Research and Development Exercises
3.4 Market Restraint
3.4.1 Uncertain Reimbursement Scenario
3.4.2 Lack of High Complexity Testing Centers
3.4.3 High Capital Requirement Hampering the Expansion of Global Reach
3.5 Market Opportunities
3.5.1 Massive Scope for Adoption of Molecular Diagnostics-Based Point of Care Products in Emerging Nations
3.5.2 Technological Advancements in Molecular Techniques and Diagnostic Tests
3.5.3 Hybridization of Technologies
4 Competitive Landscape
4.1 Key Strategies and Developments
4.1.1 Approvals
4.1.2 Synergistic Activities
4.1.3 Product Launches and Enhancements
4.1.4 Funding and Expansion Activities
4.1.5 Acquisitions
5 Global Molecular Diagnostics Point of Care Market (by Product)
5.1 Overview
5.2 Assays
5.3 Systems
5.4 Software
6 Global Molecular Diagnostics Point of Care Market (by Application)
6.1 Overview
6.2 Infectious Disease
6.2.1 Respiratory Infection
6.2.2 Hospital Acquired Infections (HAI)
6.2.3 Sexually Transmitted Infections (STIs)
6.2.4 Gastro-Intestinal Infections
6.3 Oncology
6.4 Pre-natal Testing
6.5 Others
7 Global Molecular Diagnostics Point of Care Market (by Technology)
7.1 Overview
7.2 Polymerase Chain Reaction (PCR)
7.2.1 Real-time PCR (q-PCR)
7.2.2 Digital PCR (d-PCR)
7.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
7.4 Others
8 Global Molecular Diagnostics Point of Care Market (by Region)
8.1 Overview
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.3.6 The Netherlands
8.3.7 Rest-of-Europe
8.4 Asia-Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 Singapore
8.4.6 Rest-of-APAC
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest-of-Latin America
8.6 Rest-of-the-World
9 Global Molecular Diagnostics Point of Care Market (by End-User)
9.1 Overview
9.2 Hospitals
9.3 Clinics
9.4 Diagnostic Centers
9.5 Other End-Users
10 Industry Insights
10.1 Market Share Analysis
10.2 Growth Share Analysis
11 Company Profiles
11.1 Abbott Laboratories
11.1.1 Company Overview
11.1.2 Role of Abbott Laboratories in the Global Molecular Diagnostics Point of Care Market
11.1.3 Financials
11.1.4 Key Insights about Financial Health of the Company
11.1.5 SWOT Analysis
11.2 Abacus Diagnostica Oy
11.2.1 Company Overview
11.2.2 Role of Abacus Diagnostica Oy in the Global Molecular Diagnostics Point of Care Market
11.2.3 SWOT Analysis
11.3 bioMérieux S.A.
11.3.1 Company Overview
11.3.2 Role of bioMérieux S.A. in the Global Molecular Diagnostics Point of Care Market
11.3.3 Financials
11.3.4 Key Insights about Financial Health of the Company
11.3.5 SWOT Analysis
11.4 Biocartis NV
11.4.1 Company Overview
11.4.2 Role of Biocartis NV in the Global Molecular Diagnostics Point of Care Market
11.4.3 Financials
11.4.4 Key Insights about Financial Health of the Company
11.4.5 SWOT Analysis
11.5 Danaher Corporation
11.5.1 Company Overview
11.5.2 Role of Danaher Corporation in the Global Molecular Diagnostics Point of Care Market
11.5.3 Financials
11.5.4 Key Insights about Financial Health of the Company
11.5.5 SWOT Analysis
11.6 DiaSorin S.p.A
11.6.1 Company Overview
11.6.2 Role of DiaSorin S.p.A. in the Global Molecular Diagnostics Point of Care Market
11.6.3 Financials
11.6.4 Key Insights about Financial Health of the Company
11.6.5 SWOT Analysis
11.7 DxNA LLC
11.7.1 Company Overview
11.7.2 Role of DxNA LLC in the Point of Care Global Molecular Diagnostics Point of Care Market
11.7.3 SWOT Analysis
11.8 F. Hoffmann-La Roche Ltd
11.8.1 Company Overview
11.8.2 Role of F. Hoffmann-La Roche Ltd in the Global Molecular Diagnostics Point of Care Market
11.8.3 Financials
11.8.4 Key Insights about Financial Health of the Company
11.8.5 SWOT Analysis
11.9 Luminex Corporation
11.9.1 Company Overview
11.9.2 Role of Luminex Corporation in the Global Molecular Diagnostics Point of Care Market
11.9.3 Financials
11.9.4 Key Insights about Financial Health of the Company
11.9.5 SWOT Analysis
11.10 Hologic, Inc.
11.10.1 Company Overview
11.10.2 Role of Hologic, Inc. in the Molecular Diagnostic Point of Care Market
11.10.3 Financials
11.10.4 Key Insights about Financial Health of the Company
11.10.5 SWOT Analysis
11.11 Mesa Biotech
11.11.1 Company Overview
11.11.2 Role of Mesa Biotech in the Molecular Diagnostics Point of Care Market
11.11.3 SWOT Analysis
11.12 Spartan Biosciences Inc.
11.12.1 Company Overview
11.12.2 Role of Spartan Biosciences Inc. in the Molecular Diagnostics Point of Care Market
11.12.3 SWOT Analysis
11.13 QuantuMDx Group Ltd.
11.13.1 Company Overview
11.13.2 Role of QuantuMDx Group Ltd. in the Global Molecular Diagnostics Point of Care Market
11.13.3 SWOT Analysis
11.14 Quidel Corporation
11.14.1 Company Overview
11.14.2 Role of Quidel Corporation the Global Molecular Diagnostics Point of Care Market
11.14.3 Financials
11.14.4 Key Insights about Financial Health of the Company
11.14.5 SWOT Analysis
11.15 QIAGEN N.V.
11.15.1 Company Overview
11.15.2 Role of QIAGEN N.V. in the Global Molecular Diagnostics Point of Care Market
11.15.3 Financials
11.15.4 Key Insights about Financial Health of the Company
11.15.5 SWOT Analysis
List of Tables

Table 2.1: Market Available Molecular Diagnostics Point of Care Products
Table 2.2: Classification rules of IVDs under the IVDR
Table 2.3: Registration Criteria for IVD Medical Devices as per the CFDA
Table 3.1: Impact Analysis of Market Drivers
Table 3.2: Impact Analysis of Market Restraints
Table 6.1: Global Estimates of New Cases of Curable STIs in 2016
List of Figures
Figure 1: Impact of Market Drivers and Market Restraints on the Global Molecular Diagnostics Point of Care Market
Figure 2: Global Molecular Diagnostics Point of Care Market Snapshot, 2018 and 2029
Figure 3: Dominating Segments of the Global Molecular Diagnostics Point of Care Market, 2019 and 2029
Figure 4: Key Strategies Incorporated by Stakeholders of Molecular Diagnostics Point of Care Market, to Sustain the Competition (from January 2016 to August 2019)
Figure 5: Global Molecular Diagnostics Point of Care Market Point of Care (by Product), 2018 and 2029
Figure 6: Global Molecular Diagnostics Point of Care Market (by Technology), 2018 and 2029
Figure 7: Global Molecular Diagnostics Point of Care Market (by End-User), 2018 and 2029
Figure 8: Global Molecular Diagnostics Point of Care Market (by Region) 2018 and 2029
Figure 1.1: Global Molecular Diagnostics Point-of-Care Market Segmentation
Figure 1.2: Global Molecular Diagnostics Point of Care Market Research Methodology
Figure 1.3: Primary Research
Figure 1.4: Secondary Research
Figure 1.5: Data Triangulation
Figure 1.6: Bottom-Up Approach (Segment-Wise Analysis)
Figure 1.7: Top-Down Approach (Segment-Wise Analysis)
Figure 1.8: Assumptions and Limitations
Figure 1.9: Considered Factors for Data Prediction and Modeling
Figure 2.1: Characteristics of a Commercially Available Molecular Diagnostics Point of Care Products
Figure 2.2: Components Considered for Clinical Evidence as per the IVDR
Figure 3.1: Number of Deaths due to top 18 Infectious Diseases on a Global Scale, 2015
Figure 3.2: Number of Deaths due to Different Forms of Cancer, Million Units, 2018,
Figure 4.1: Share of Key Developments and Strategies, January 2016 – August 2019
Figure 4.2: Approvals Share (by Company), January 2016 – August 2019
Figure 4.3: Synergistic Activities Share (by Company), January 2016 – August 2019
Figure 4.4: Product Launches and Enhancements Share (by Company), January 2016 – August 2019
Figure 4.5: Funding Share (by Company), January 2016 – August 2019
Figure 4.6: Acquisitions Share (by Company), January 2016 – August 2019
Figure 5.1: Global Molecular Diagnostics Point of Care Market (by Product)
Figure 5.2: Global Molecular Diagnostics Point of Care Market (by Product), 2018-2029
Figure 5.3: General Workflow of a Molecular Diagnostics Point of Care Kit
Figure 5.4: Global Molecular Diagnostics Point of Care Market (Assays), 2018-2029
Figure 5.5: Global Molecular Diagnostics Point of Care Market (by Systems), 2018-2029
Figure 5.7: Aspects of Software Development
Figure 5.8: Global Molecular Diagnostics Point of Care Market (by Software), 2018-2029
Figure 6.1: Global Molecular Diagnostics Point of Care Market (by Application), 2018-2029
Figure 6.2: Global Molecular Diagnostics Point of Care Market (by Infectious Disease), 2018-2029
Figure 6.3: Global Molecular Diagnostics Point of Care Market (by Infectious Disease Type), 2018-2020
Figure 6.4: Global Molecular Diagnostics Point of Care Market (by Respiratory Infections), 2018-2029
Figure 6.5: Global Molecular Diagnostics Point of Care Market (by Hospital Acquired Infections), 2018-2029
Figure 6.6: Global Molecular Diagnostics Point of Care Market (by Sexually Transmitted Infections), 2018-2029
Figure 6.7: Global Molecular Diagnostics Point of Care Market (by Gastro-Intestinal Infections), 2018-2029
Figure 6.8: Global Molecular Diagnostics Point of Care Market (by Oncology), 2018-2029
Figure 6.9: Global Molecular Diagnostics Point of Care Market (by Pre-natal Testing), 2018-2029
Figure 6.10: Global Molecular Diagnostics Point of Care Market (by Other Applications), 2018-2029
Figure 7.1: Global Molecular Diagnostics Point of Care Market (by Technology), 2018-2029
Figure 7.2: Global Molecular Diagnostics Point of Care Market (by PCR), 2018-2029
Figure 7.3: Global Molecular Diagnostics Point of Care Market (by q-PCR), 2018-2029
Figure 7.4: Global Molecular Diagnostics Point of Care Market (by d-PCR), 2020-2029
Figure 7.5: Global Molecular Diagnostics Point of Care Market (by INAAT), 2018-2029
Figure 7.6: Global Molecular Diagnostics Point of Care Market (by Other Technologies), 2018-2029
Figure 8.1: Global Molecular Diagnostics Point of Care Market (by Region), 2018 and 2029
Figure 8.2: Global Molecular Diagnostics Point of Care Market Point of Care (by Region), 2018-2029
Figure 8.3: Global Molecular Diagnostics Point of Care Market Share (by Region), 2018
Figure 8.4: Global Molecular Diagnostics Point of Care Market Share (by Region), 2029
Figure 8.5: North America Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.6: North America Molecular Diagnostics Point of Care Market (by Country), 2018-2029
Figure 8.7: North America: Market Dynamics
Figure 8.8: The U.S. Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.9: Canada Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.10: Overview of Reimbursement Policies in Europe (Focus on Companion Diagnostics as well)
Figure 8.11: Europe Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.12: Europe: Market Dynamics
Figure 8.13: Europe Molecular Diagnostics Point of Care Market (by Country), 2018-2029
Figure 8.14: Germany Point of Care Molecular Diagnostics Market, 2018-2029
Figure 8.15: U.K. Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.16: France Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.17: Italy Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8 18: Spain Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.19: The Netherlands Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.20: Rest-of-Europe Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.21: Asia-Pacific Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.22: APAC: Market Dynamics
Figure 8.23: APAC Global Molecular Diagnostics Point of Care Market (by Country), 2018-2029
Figure 8.24: China Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.25: Japan Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.26: India Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.27: Australia Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.28: Singapore Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.29: RoAPAC Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.30: Latin America Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.31: Latin America: Market Dynamics
Figure 8.32: Latin America Molecular Diagnostics Point of Care Market (by Country), 2018-2029
Figure 8.33: Brazil Molecular Diagnostics Point of Care Market 2018-2029
Figure 8.34: Mexico Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.35: Rest-of-Latin America Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.36: RoW Molecular Diagnostics Point of Care Market, 2018-2029
Figure 9.1: Global Molecular Diagnostics Point of Care Market (by End-User)
Figure 9.2: Global Molecular Diagnostics Point of Care Market (by End User), 2018-2029
Figure 9.3: Global Molecular Diagnostics Point of Care Market (by Hospitals), 2018-2029
Figure 9.4: Global Molecular Diagnostics Point of Care Market (by Clinics), 2018-2029
Figure 9.5: Global Molecular Diagnostics Point of Care Market (Diagnostic Centers), 2018-2029
Figure 9.6: Global Molecular Diagnostics Point of Care Market (by Other End-Users), 2018-2029
Figure 10.1: Market Share Analysis for the Global Molecular Diagnostics Point of Care Market, 2018
Figure 10.2: Growth Share Matrix for Molecular Diagnostics Point of Care Market (by Company), 2018
Figure 11.1: Total Number of Companies Profiled
Figure 11.2: Abbott Laboratories: Overall Product Portfolio
Figure 11.3: Abbott Laboratories: Overall Financials, 2016-2018
Figure 11.4: Abbott Laboratories: Revenue (by Segment), 2016-2018
Figure 11.5: Abbott Laboratories: Revenue Split for Diagnostics, 2016-2018
Figure 11.6: Abbott Laboratories: Revenue (by Region), 2016-2018
Figure 11.7: Abbott Laboratories: R&D Expenditure, 2016-2018
Figure 11.8: Abbott Laboratories: SWOT Analysis
Figure 11.9: Abacus Diagnostica Oy.: Overall Product Portfolio (Available from FY2019)
Figure 11.10: Abacus Diagnostica Oy: SWOT Analysis
Figure 11.11: bioMérieux S.A.: Overall Product Portfolio
Figure 11.12: bioMérieux S.A.: Overall Financials, 2016-2018
Figure 11.13: bioMérieux S.A.: Revenue (by Segment), 2016-2018
Figure 11.14: bioMérieux S.A.: Revenue (by Region), 2016-2018
Figure 11.15: bioMérieux S.A.: R&D Expenditure, 2016-2018
Figure 11.16: bioMérieux S.A.: SWOT Analysis
Figure 11.17: Biocartis NV: Overall Product Portfolio
Figure 11.18: Biocartis NV: Overall Financials, 2016-2018
Figure 11.19: Biocartis NV: R&D Expenditure, 2016-2018
Figure 11.20: Biocartis NV: SWOT Analysis
Figure 11.21: Danaher Corporation: Molecular Diagnostics Point of Care Product Portfolio
Figure 11.22: Danaher Corporation: Overall Financials, 2016-2018
Figure 11.23: Danaher Corporation: Revenue (by Business Segment), 2016-2018
Figure 11.24: Danaher Corporation: Revenue (by Region), 2016-2018
Figure 11.25: Danaher Corporation: R&D Expenditure, 2016-2018
Figure 11.26: Danaher Corporation: SWOT Analysis
Figure 11.27: DiaSorin S.p.A.: Overall Financials, 2016-2018
Figure 11.28: DiaSorin S.p.A.: Revenue (by Segment), 2016-2018
Figure 11.29: DiaSorin S.p.A.: By Region, 2016-2018
Figure 11.30: DiaSorin S.p.A: R&D Expenditure, 2016-2018
Figure 11.31: DiaSorin S.p.A: SWOT Analysis
Figure 11.32: DxNA LLC.: Overall Product Portfolio (Available from FY2019)
Figure 11.33: DxNA LLC Group Ltd.: SWOT Analysis
Figure 11.34: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 11.35: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 11.36: F. Hoffmann-La Roche Ltd: Overall Financials, 2016-2018
Figure 11.37: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2016-2018
Figure 11.38: F. Hoffmann-La Roche Ltd: Revenue Split for Diagnostics, 2016-2018
Figure 11.39: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2016-2018
Figure 11.40: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2016-2018
Figure 11.41: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 11.42: Luminex Corporation: Overall Product Portfolio
Figure 11.43: Luminex Corporation: Overall Financials, 2016-2018
Figure 11.44: Luminex Corporation: Revenue (by Segment), 2016-2018
Figure 11.45: Luminex Corporation: Revenue (by Region), 2016-2018
Figure 11.46: Luminex Corporation: R&D Expenditure, 2016-2018
Figure 11.47: Luminex Corporation: SWOT Analysis
Figure 11.48: Hologic, Inc.: Overall Product Portfolio
Figure 11.49: Hologic, Inc.: Overall Financials, 2016-2018
Figure 11.50: Hologic, Inc.: Revenue (by Segment), 2016-2018
Figure 11.51: Hologic, Inc.: Revenue (by Region), 2016-2018
Figure 11.52: Hologic, Inc.: R&D Expenditure, 2016-2018
Figure 11.53: Hologic, Inc.: SWOT Analysis
Figure 11.54: Mesa Biotech: Overall Product Portfolio (Available from FY2019)
Figure 11.55: Mesa Biotech: SWOT Analysis
Figure 11.56: Spartan Biosciences Inc.: Overall Product Portfolio (Available from FY2019)
Figure 11.57: Spartan Biosciences, Inc.: SWOT Analysis
Figure 11.58: QuantuMDx Group Ltd.: Overall Product Portfolio (Available from FY2019)
Figure 11.59: QuantuMDx Group Ltd.: SWOT Analysis
Figure 11.60: Quidel Corporation Ltd.: Overall Product Portfolio (Available from FY2019)
Figure 11.61: Quidel Corporation: Overall Financials, 2016-2018
Figure 11.62: Quidel Corporation: Revenue (by Segment), 2016-2018
Figure 11.63: Quidel Corporation: Revenue (by Region), 2016-2018
Figure 11.64: Quidel Corporation: R&D Expenditure, 2016-2018
Figure 11.65: Quidel Corporation: SWOT Analysis
Figure 11.66: QIAGEN N.V.: Overall Product Portfolio
Figure 11.67: QIAGEN N.V.: Overall Financials, 2016-2018
Figure 11.68: QIAGEN N.V.: Revenue (by Segment), 2016-2018
Figure 11.69: QIAGEN N.V.: Revenue (by Region), 2016-2018
Figure 11.70: QIAGEN N.V.: R&D Expenditure, 2016-2018
Figure 11.71: QIAGEN N.V.: SWOT Analysis
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
The Netherlands
Rest-of-Europe
Asia-Pacific
China
Japan
India
Australia
Singapore
Rest-of-APAC
Latin America
Brazil
Mexico
Rest-of-Latin America
Rest-of-the-World
Molecular Diagnostics Point of Care Market Report, Molecular Diagnostics Point of Care Report, Molecular Diagnostics Point of Care Industry, Molecular Diagnostics Point of Care Market Size, Molecular Diagnostics Point of Care Market Share, Molecular Diagnostics Point of Care Market Forecast, Molecular Diagnostics Point of Care Market Growth, Molecular Diagnostics Point of Care Market Opportunity, Molecular Diagnostics Point of Care Industry Size, Molecular Diagnostics Point of Care Market Outlook, Molecular Diagnostics Point of Care Market Trends Molecular Diagnostics Point of Care Market Segments, Molecular Diagnostics Point of Care Market Drivers, Molecular Diagnostics Point of Care Market Competitive Landscape, Molecular Diagnostics Point of Care Market Industry Insights, Molecular Diagnostics Point of Care Market by Type, Molecular Diagnostics Point of Care Industry Outlook, Molecular Diagnostics Point of Care Industry Trends, Molecular Diagnostics Point of Care Industry share, Molecular Diagnostics Point of Care Industry Forecast, Molecular Diagnostics POC Report, Molecular Diagnostics POC Industry, Molecular Diagnostics POC Market Size, Molecular Diagnostics POC Market Share, Molecular Diagnostics POC Market Forecast, Molecular Diagnostics POC Market Growth, Molecular Diagnostics POC Market Opportunity, Molecular Diagnostics POC Industry Size
According to a new market intelligence report by BIS Research titled “Global Molecular Diagnostic Point of Care Market- Analysis and Forecast, 2019-2029”, the global molecular diagnostic point of care market was valued at $1.68 billion in 2018 and is anticipated to grow over $6.02 billion by 2029. The global molecular diagnostic point of care market is expected to grow at a double-digit compound annual growth rate in the forecast period 2019-2029, aided primarily by the impressive growth in the underlying manufacturing market.
On a broader horizon, the domain of healthcare diagnostics is constituted of two primary areas, in-vivo imaging, and in-vitro diagnostics. In-vivo imaging encompasses technologies including X-Rays, ultrasonic waves, magnetic resonance, and radio-nuclear methods that allow the visualization of the body, its organs, and other structures of importance. In-vitro diagnostics are medical devices and accessories that are utilized for the testing of samples that have been extracted from the human body for the detection of infection, diagnosis of medical condition, and prevention of disease. One of the revolutionary breakthroughs which in-vitro diagnostics has resulted in is diagnosis at a molecular level. Molecular diagnostics involve a detailed study of nucleic acids and proteins to diagnose and characterize the diseases, resulting in target-based treatment of diseases. This treatment approach based on biomarker study is perceived to be promising in driving a paradigm shift in the healthcare industry, facilitating elimination of the uncertainty pertaining to the trial-and-error method of medications, and certainly eliminating unnecessary healthcare spending. Therefore, molecular diagnostics has been receiving considerable acceptance in the medical community. Another breakthrough in the field of in-vitro diagnostics is point of care technology (POCT). The technological advancements such as miniaturization, nanotechnology and microfluidics have been pushing this cloud-connected point of care technology toward specificity and sensitivity at reduced cost and rapid turnaround time. The amalgamation of both the technologies has led the clinical molecular testing toward decentralized molecular diagnostics.
“North America is the leading contributor in the molecular diagnostic point of care market and contributed approximately 42.18% to the global market value in 2018. This region is anticipated to grow at a CAGR of 11.75% during the forecast period 2019-2029 and continue dominating the global market in 2029 as well. However, the Asia-Pacific region is expected to grow at an impressive CAGR of 12.56% during the forecast period from 2019-2029. The Europe region also contributed a significant share of 27.27% to the global market and is anticipated to grow at a CAGR of 12.44% during the forecast period from 2019-2029.”
Research Highlights:
• Infectious disease segment is the leading contributor in molecular diagnostic point of care market and contributed approximately 71.16% in the global market value. However, the molecular diagnostic point of care market for oncology is anticipated to witness the fastest growth of 14.11% during the forecast period 2019-2029.
• F. Hoffmann-La Roche AG is currently the largest shareholder in the global molecular diagnostic point of care market. This market dominance is attributed to the company’s presence within the market through its expansive product portfolio, led by dedicated products.
Source: BIS Research Analysis
This market intelligence report provides a multi-dimensional view of the global molecular diagnostic point of care market in terms of market size and growth potential. This research report aims at answering various aspects of the global molecular diagnostic point of care market with the help of key factors driving the market, restraints that can possibly inhibit the overall growth of the market, and the current growth opportunities that are going to shape the future trajectory of the market expansion.
Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with the recent market activities, such as product launches and approvals, partnerships, collaborations, business expansions, as well as mergers and acquisitions, among others. The research report provides a comprehensive analysis of the product sales, manufacturers, service providers, and trend analysis by segment, and growth share analysis by region. Additionally, the report provides a comprehensive attractive analysis and opportunity analysis for the entire global molecular diagnostic point of care market for 2019 and 2029.
This report is a meticulous compilation of research on more than 50 players in the market ecosystem and draws upon insights from in-depth interviews with the key opinion leaders of more than 15 leading companies, market participants, and vendors. The report also comprises 15 detailed company profiles including several key players, such as Hologic, Inc., Abbott Laboratories, bioMerieux S.A., QIAGEN N.V., Quidel Corporation, Biocartis NV, Danaher Corporation, DiaSorin S.p.A., F. Hoffman-La Roche Ltd., Luminex Corporation, Mesa Biotech, QuantuMDx Group Ltd., Spartan Biosciences Inc., DxNA LLC, and Abacus Diagnostica Oy.
The answers to the following key questions can be derived from this report:
• What are the major market drivers, challenges, and opportunities in the global molecular diagnostic point of care market?
• What are the factors resulting in the emerging trends within the global molecular diagnostic point of care market?
• How is each segment expected to grow in the global molecular diagnostic point of care market during the forecast period and what is the estimated revenue to be generated by each of the segments by the end of 2029?
• What are the key developmental strategies which are implemented by the major players in order to sustain in the competitive market? What are the key regulatory implications in developed and developing regions for molecular diagnostic point of care market?
• Who are the leading players with significant offerings to the global molecular diagnostic point of care market? What is the current market dominance for each of these leading players?
• What is the compound growth rate expected to be witnessed by the leading players in the market during the forecast period 2019-2029?
• What are the key applications in global molecular diagnostic point of care market? What are the major segments of these applications?
• Which are the dominant methods of the global molecular diagnostic point of care market? Which is the fastest growing method in the global molecular diagnostic point of care market?
• Who are the key manufacturers and service providers in the global molecular diagnostic point of care market, and what are their contributions? Also, what is the growth potential of each major molecular point of care diagnostic manufacturer?
• What is the scope of the global molecular diagnostic point of care market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World? Which therapeutic application type dominates these regions?
Key trends targeted in the report:
• What are the emerging trends in the global molecular diagnostic point of care market? How are these trends revolutionizing the current diagnosis?
• Which companies are anticipated to be highly disruptive in the future and why?
• What are the gaps in regularizing optimum molecular diagnostic based point of care test? How are these gaps being tackled?
Abbott Laboratories
Abacus Diagnostica Oy
bioMérieux S.A.
Biocartis NV
Danaher Corporation
DiaSorin S.p.A
DxNA LLC
F. Hoffmann-La Roche Ltd
Luminex Corporation
Hologic, Inc.
Mesa Biotech
Spartan Biosciences Inc.
QuantuMDx Group Ltd.
Quidel Corporation
QIAGEN N.V.
Global Molecular Diagnostic Point of Care Market to Reach $6.02 Billion by 2029

Additional Info

Author BIS Research INC.
Published by BISRESEARCH
Document type Report
Number of pages 238